Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
about
Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new dataPost-operative radiation therapyN2-IIIA non-small cell lung cancer: a plea for surgery!Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients.Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLCRole of adjuvant radiotherapy in completely resected non-small-cell lung cancer.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery.Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimenThe effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapyClinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancerPrognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment.Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the PrognosisHistopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyThe role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?Surgery following neoadjuvant chemotherapy for non-small-cell lung cancer patients with unexpected persistent pathological N2 disease.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy.Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery.Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerWhat is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?Controversies in the management of stage IIIA non-small-cell lung cancer.Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer.Treatment in resectable, locally advanced NSCLC: which is the best approach?Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures.Radiotherapy for single station N2 NSCLC.The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.A closer look at the safety and effectiveness of modern PORT in stage III-N2 non-small cell lung cancer.Optimized local therapy for locally advanced non-small cell lung cancer.Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.Mediastinal lymphadenectomy in elderly patients with non-small-cell lung cancer.
P2860
Q24633254-FE4F1BE6-CCCF-42A9-803D-AA76EFCFFA6EQ26830376-84D047D9-3B17-4E59-9401-1799A1555932Q28069001-0BB7676A-A000-489D-9A1D-1312F6D66D4CQ33372250-A040F1D7-D493-45AA-ADCA-D60EFDA529CBQ33568631-0E497B8D-AF52-4D73-89F6-B71130AC6E25Q33584618-2A1EF0B5-1B81-4F5D-B991-39361FACFEFFQ33698439-85D0E000-FA62-4338-93A9-785721EA1BB6Q33886353-4DBDD639-630F-4883-A47E-63A58D9F1761Q34314653-78D3216C-3E5D-4DB4-80C9-4D4C893846C5Q34420618-4E7D8D2C-4DA2-4A60-9378-A24F16DCC3D8Q34493493-0C34A350-3B54-407B-A360-47C24B82095EQ34720945-335668E9-C577-4E08-A1F7-D0127281E8C6Q35540726-A5167BF0-FE2D-4048-A831-8A6A51BB3292Q35634785-9863B36D-6563-4BEC-A4D2-145FA849E175Q35644940-11FF04ED-3289-472C-92F8-FA354819A220Q36195470-A77F744A-EF9F-4EB6-BA92-A66BEB27C8FAQ36302496-63E4FFD2-D680-4034-B2CA-79DA539ED1CCQ36308285-A15CDFC3-BA1E-4B7A-8EA6-AEA9EDB8A7F4Q36408837-D1BF781D-23DC-4D60-9ACC-94A37BD14A3BQ36524101-276A890A-2965-4AD6-BB3B-F02364514AE1Q36525431-51C54E2E-AEC6-4CB1-A1CE-DB1C2E0DF551Q36614079-9A260371-1C52-4054-803C-BE09CE9343EEQ36614143-D0249B90-5CBF-43C1-B670-0043F54F7EDFQ36835919-59E12F42-B9A8-4D51-8C46-636ABB4643BFQ36850130-004C91D1-08B4-457A-92E4-CD6D0E20A36CQ36989648-06A7498D-6B51-4EAF-930C-FFA01D26491FQ37085999-2A96D21A-FEC3-4470-8857-D830A0ED84BFQ37338248-33AD6383-26A8-4906-B105-B2415FB66A6AQ37624187-11110AFF-AD06-4394-ADB3-E4360ABA25F5Q37742200-42209119-DA22-46D7-A8E7-5D470F35AF34Q37755004-A75EDE25-39B2-4D3D-A496-C6D9CD1E0CD1Q37812887-BFE4CA47-577B-495C-9301-8A8578DFF1F9Q38390158-AD9C6F10-0C7D-46CB-88F3-074E332D31AFQ38607262-1864E638-29B5-487C-8882-6A45A6212D60Q38696794-9E73ED61-0A0B-4A94-892C-FF9355915903Q39024864-C377E7CA-C85C-4FC8-B94A-AE60004E9C91Q40987021-E77B4D18-7234-4B64-B0BB-53641A686901Q42341998-AD098C86-5F22-47D5-96C7-7E22D499ECCEQ44300864-B7764ED2-33BD-4951-9135-4A8BED40B625Q45825288-2543C85A-E6EA-473E-95FC-712A5631819D
P2860
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@ast
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@en
type
label
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@ast
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@en
prefLabel
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@ast
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@en
P2093
P921
P356
P1476
Mediastinal lymph node clearan ...... a multicenter phase II trial.
@en
P2093
Anastase Spiliopoulos
Arnaud D Roth
Christian von Briel
Christine Joss
Daniel C Betticher
Eva Hansen
Fritz Egli
Hans-Beat Ris
Hanspeter Honegger
James Habicht
P304
P356
10.1200/JCO.2003.11.040
P407
P577
2003-05-01T00:00:00Z